{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Nuvation+Bio+Inc.", "query": { "sponsor": "Nuvation Bio Inc." }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T00:05:17.407Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05191017", "title": "Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Prostatic Cancer", "Cancer of Prostate", "Cancer of the Prostate", "Prostate Neoplasm", "Castrate Resistant Prostate Cancer", "Castration Resistant Prostatic Cancer", "Castration Resistant Prostatic Neoplasms" ], "interventions": [ { "name": "NUV-422", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-09", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2022-08-05", "last_synced_at": "2026-09-30T00:05:17.407Z", "location_count": 3, "location_summary": "Canton, Ohio • Gettysburg, Pennsylvania • Fairfax, Virginia", "locations": [ { "city": "Canton", "state": "Ohio" }, { "city": "Gettysburg", "state": "Pennsylvania" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05191017" }, { "nct_id": "NCT07703436", "title": "Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Grade 2 IDH1-mutant Glioma", "Grade 3 IDH1-mutant Glioma", "Glioma", "IDH1-mutant Glioma", "Oligodendroglioma", "Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted", "Astrocytoma IDH Mutant Grade 3", "Astrocytoma IDH Mutant Grade 2" ], "interventions": [ { "name": "Safusidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2027-03", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-09-30T00:05:17.407Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • New Haven, Connecticut + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07703436" }, { "nct_id": "NCT07154706", "title": "Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Taletrectinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2025-08-21", "completion_date": "2033-08-30", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-09-30T00:05:17.407Z", "location_count": 12, "location_summary": "Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT07154706" }, { "nct_id": "NCT06334432", "title": "Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "HER2-negative Breast Cancer", "Metastatic Castration-resistant Prostate Cancer (mCRPC)", "Pancreatic Cancer", "Platinum-resistant Ovarian Cancer (PROC)" ], "interventions": [ { "name": "NUV-1511", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 466, "start_date": "2024-03-14", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-09-30T00:05:17.407Z", "location_count": 8, "location_summary": "Detroit, Michigan • Hackensack, New Jersey • New York, New York + 5 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06334432" }, { "nct_id": "NCT02279433", "title": "A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "DS6051b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2014-09", "completion_date": "2019-03", "has_results": false, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-09-30T00:05:17.407Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Orange, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02279433" }, { "nct_id": "NCT04919811", "title": "Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Taletrectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 217, "start_date": "2021-09-01", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-09-30T00:05:17.407Z", "location_count": 20, "location_summary": "Beverly Hills, California • Glendale, California • La Jolla, California + 17 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04919811" }, { "nct_id": "NCT05303519", "title": "SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioma", "Astrocytoma, Grade IV", "IDH1-mutant Glioma", "Astrocytoma, IDH-Mutant, Grade 3", "Astrocytoma, IDH-Mutant, Grade 4", "Astrocytoma, IDH-Mutant, Grade 2", "Oligodendroglioma", "Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted" ], "interventions": [ { "name": "safusidenib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 365, "start_date": "2023-06-05", "completion_date": "2030-12-01", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-30T00:05:17.407Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05303519" }, { "nct_id": "NCT05191004", "title": "Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer", "Breast Cancer", "Breast Carcinoma", "Cancer of the Breast", "Cancer of Breast", "Malignant Tumor of Breast", "Breast Tumor" ], "interventions": [ { "name": "NUV-422", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-09", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2023-07-11", "last_synced_at": "2026-09-30T00:05:17.407Z", "location_count": 5, "location_summary": "Anaheim, California • Fountain Valley, California • Canton, Ohio + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Canton", "state": "Ohio" }, { "city": "Gettysburg", "state": "Pennsylvania" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05191004" }, { "nct_id": "NCT05252390", "title": "NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Ovarian Cancer", "Ovary Cancer", "Cancer of Ovary", "Cancer of the Ovary", "Ovary Neoplasm", "Pancreatic Cancer", "Pancreas Cancer", "Cancer of Pancreas", "Cancer of the Pancreas", "Pancreas Neoplasm", "Prostate Cancer", "Prostatic Cancer", "Cancer of Prostate", "Cancer of the Prostate", "Prostate Neoplasm", "Castrate Resistant Prostate Cancer", "Castration Resistant Prostatic Cancer", "Castration Resistant Prostatic Neoplasms", "Triple-negative Breast Cancer", "Triple Negative Breast Cancer", "Triple Negative Breast Neoplasms", "Breast Cancer", "Breast Carcinoma", "Cancer of Breast", "Cancer of the Breast", "Breast Tumor" ], "interventions": [ { "name": "NUV-868", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2022-03-29", "completion_date": "2024-07-15", "has_results": false, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-09-30T00:05:17.407Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05252390" }, { "nct_id": "NCT04541225", "title": "Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Glioma, Malignant", "Glioma, Mixed", "Glial Cell Tumors", "Breast Cancer", "Breast Carcinoma", "Cancer of Breast", "Cancer of the Breast", "Breast Tumor", "Malignant Tumor of Breast", "Advanced Breast Cancer", "Advanced Breast Carcinoma", "Metastatic Breast Cancer", "Metastatic Breast Carcinoma", "Prostate Cancer", "Prostatic Cancer", "Cancer of Prostate", "Cancer of the Prostate", "Prostate Neoplasm", "Castrate Resistant Prostate Cancer", "Castration-resistant Prostate Cancer", "Castration Resistant Prostatic Neoplasms", "Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "NUV-422", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2020-12-08", "completion_date": "2022-08-31", "has_results": false, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-09-30T00:05:17.407Z", "location_count": 12, "location_summary": "Tucson, Arizona • Miami, Florida • Boston, Massachusetts + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04541225" } ] }